Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 6,665 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $59.12, for a total transaction of $394,034.80. Following the completion of the sale, the insider now owns 267,463 shares of the company's stock, valued at $15,812,412.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, October 2nd, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $56.26, for a total transaction of $374,972.90.
• On Wednesday, September 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $47.56, for a total transaction of $316,987.40.

Apogee Therapeutics Stock Performance

Shares of NASDAQ:APGE traded up $3.07 during trading on Friday, reaching $61.12. The stock had a trading volume of 407,357 shares, compared to its average volume of 496,236. The firm's fifty day moving average is $54.05 and its 200 day moving average is $48.70. Apogee Therapeutics, Inc. has a 52 week low of $14.19 and a 52 week high of $72.29. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of -29.53 and a beta of 2.93.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.60). On average, research analysts forecast that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in Apogee Therapeutics by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company's stock worth $94,000 after buying an additional 285 shares during the last quarter. EntryPoint Capital LLC raised its holdings in Apogee Therapeutics by 44.7% during the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company's stock worth $133,000 after buying an additional 617 shares during the last quarter. Kennedy Capital Management LLC acquired a new position in Apogee Therapeutics during the first quarter worth $212,000. Allspring Global Investments Holdings LLC acquired a new position in Apogee Therapeutics during the second quarter worth $143,000. Finally, Ameritas Investment Partners Inc. raised its holdings in Apogee Therapeutics by 111.2% during the first quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company's stock worth $274,000 after buying an additional 2,172 shares during the last quarter. Institutional investors and hedge funds own 79.04% of the company's stock.

Analyst Ratings Changes

Separately, Wedbush reiterated an "outperform" rating and issued a $87.00 price objective on shares of Apogee Therapeutics in a research note on Friday, October 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $78.50.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.